Template-Derived Engineering of Peptide Inhibitors Targeting HSP90–CDC37 Interface: A Theoretical Framework for Cancer Therapeutics

IF 2.3 4区 化学 Q3 CHEMISTRY, MULTIDISCIPLINARY
ChemistrySelect Pub Date : 2026-09-23 DOI:10.1002/slct.74551
Sarath Perumal, Ramanathan Karuppasamy
{"title":"Template-Derived Engineering of Peptide Inhibitors Targeting HSP90–CDC37 Interface: A Theoretical Framework for Cancer Therapeutics","authors":"Sarath Perumal,&nbsp;Ramanathan Karuppasamy","doi":"10.1002/slct.74551","DOIUrl":null,"url":null,"abstract":"<div>\n \n <p>The HSP90–CDC37 complex plays a key role in stabilizing multiple oncogenic client proteins, thereby sustaining cancer cell survival. However, targeting these dynamic interfaces remains challenging due to the large, shallow binding surfaces, which limit the effectiveness of conventional small-molecule inhibitors. Peptide-based therapeutics offer a promising alternative owing to their ability to mimic native motifs. Two continuous interfacial segments from CDC37 were extracted to construct template peptides, which were used to generate peptide libraries. A multi-level hierarchical screening strategy was applied to evaluate 4050 and 843,750 sequences derived from Template-1 and Template-2, respectively, thereby prioritizing top candidates based on binding profiles and physicochemical suitability. The shortlisted peptides were further validated using the Boltz-2 deep learning framework to enhance confidence in the predicted peptide structures and protein–peptide complexes. Binding free-energy and molecular dynamics simulation analyses were subsequently performed to assess their interaction with HSP90. The lead peptide was then benchmarked against positive and negative controls to provide a relative assessment of its binding performance. Collectively, these findings identify Pep14 derived from Template-2 as a lead peptide candidate for disrupting the HSP90–CDC37 interaction. However, further experimental validation is required to confirm its therapeutic potential in cancer treatment.</p>\n </div>","PeriodicalId":146,"journal":{"name":"ChemistrySelect","volume":"11 37","pages":""},"PeriodicalIF":2.3000,"publicationDate":"2026-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ChemistrySelect","FirstCategoryId":"92","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/slct.74551","RegionNum":4,"RegionCategory":"化学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CHEMISTRY, MULTIDISCIPLINARY","Score":null,"Total":0}
引用次数: 0

Abstract

The HSP90–CDC37 complex plays a key role in stabilizing multiple oncogenic client proteins, thereby sustaining cancer cell survival. However, targeting these dynamic interfaces remains challenging due to the large, shallow binding surfaces, which limit the effectiveness of conventional small-molecule inhibitors. Peptide-based therapeutics offer a promising alternative owing to their ability to mimic native motifs. Two continuous interfacial segments from CDC37 were extracted to construct template peptides, which were used to generate peptide libraries. A multi-level hierarchical screening strategy was applied to evaluate 4050 and 843,750 sequences derived from Template-1 and Template-2, respectively, thereby prioritizing top candidates based on binding profiles and physicochemical suitability. The shortlisted peptides were further validated using the Boltz-2 deep learning framework to enhance confidence in the predicted peptide structures and protein–peptide complexes. Binding free-energy and molecular dynamics simulation analyses were subsequently performed to assess their interaction with HSP90. The lead peptide was then benchmarked against positive and negative controls to provide a relative assessment of its binding performance. Collectively, these findings identify Pep14 derived from Template-2 as a lead peptide candidate for disrupting the HSP90–CDC37 interaction. However, further experimental validation is required to confirm its therapeutic potential in cancer treatment.

靶向HSP90-CDC37界面的肽抑制剂的模板衍生工程:癌症治疗的理论框架
HSP90-CDC37复合物在稳定多种致癌客户蛋白中发挥关键作用,从而维持癌细胞存活。然而,由于大而浅的结合表面限制了传统小分子抑制剂的有效性,靶向这些动态界面仍然具有挑战性。基于肽的治疗方法提供了一个有希望的替代方案,因为它们能够模仿天然基序。从CDC37中提取两个连续的界面片段构建模板肽,用于生成肽库。采用多层次筛选策略,分别对Template-1和Template-2衍生的4050和843750个序列进行了评估,从而根据结合谱和物理化学适用性对候选序列进行优先排序。使用Boltz-2深度学习框架进一步验证入围肽,以提高对预测肽结构和蛋白-肽复合物的信心。随后进行结合自由能和分子动力学模拟分析,以评估它们与HSP90的相互作用。然后将导联肽与阳性和阴性对照对照,以提供其结合性能的相对评估。总的来说,这些发现确定了来自Template-2的Pep14作为破坏HSP90-CDC37相互作用的先导肽候选。然而,需要进一步的实验验证来证实其在癌症治疗中的治疗潜力。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
ChemistrySelect
ChemistrySelect Chemistry-General Chemistry
CiteScore
3.30
自引率
4.80%
发文量
1809
审稿时长
1.6 months
期刊介绍: ChemistrySelect is the latest journal from ChemPubSoc Europe and Wiley-VCH. It offers researchers a quality society-owned journal in which to publish their work in all areas of chemistry. Manuscripts are evaluated by active researchers to ensure they add meaningfully to the scientific literature, and those accepted are processed quickly to ensure rapid online publication.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书